The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland-Reference-Cited by-同舟云学术

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

Published:2022-08-04 Issue:5 Volume:6 Page:757-771
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Ward Thomas,Brown Tray,Lewis Ruth D.,Kliess Melodi Kosaner,de Arellano Antonio Ramirez,Quinn Carol M.

Funder

Vifor Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00357-z.pdf

Reference98 articles.

1. Hougen I, Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int Rep. 2021;6(5):1309–16.

2. Wiebe N, Klarenbach SW, Allan GM, Manns BJ, Pelletier R, James MT, et al. Potentially preventable hospitalization as a complication of CKD: a cohort study. Am J Kidney Dis. 2014;64(2):230–8.

3. Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–21.

4. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, et al. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2015;41(6):456–63.

5. Khanagavi J, Gupta T, Aronow WS, Shah T, Garg J, Ahn C, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;10(2):251.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart Failure and Edema Costs in Patiromer and Sodium Zirconium Cyclosilicate Users;Kidney360;2024-06-05

2. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study;Cost Effectiveness and Resource Allocation;2024-05-21

3. Cost‐effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore;Nephrology;2024-03-05

4. Prediction of Chronic Kidney Disease Using ML Techniques;2024 IEEE International Conference on Computing, Power and Communication Technologies (IC2PCT);2024-02-09

5. Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…;Clinical Kidney Journal;2023-04-21